Jul 31, 2012 9:00 am EDT Lixte Biotechnology Holdings Announces Increased Funding And FDA Allowance To Conduct A Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
May 1, 2012 12:00 pm EDT Lixte Biotechnology Holdings Announces Submission of an IND to the FDA for Approval of a Clinical Trial of LB-100, a First-in-Class, Anti-Cancer Compound
Apr 4, 2012 9:30 am EDT Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor
Jan 9, 2012 9:00 am EST Lixte Biotechnology Holdings Announces Issuance of U.S. Patent for Agents for the Treatment of Neurodegenerative Diseases
Dec 19, 2011 9:00 am EST Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease
Sep 22, 2011 9:00 am EDT Lixte Biotechnology Holdings Announces Issuance of U.S. Patent for Lead Anti-Cancer Compound
May 25, 2011 9:00 am EDT Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
Mar 2, 2011 10:39 am EST Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government
Oct 5, 2010 9:00 am EDT Lixte Biotechnology Holdings, Inc. Announces the Approval of a Collaboration with the National Cancer Institute for Clinical Evaluation of its Lead Anti-Cancer Compound, LB-100.
Jul 2, 2009 9:00 am EDT Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models
